Could a monoclonal antibody treat peanut allergy?

Peanuts

IgGenix has made advances towards a peanut allergy therapeutic based on IgG4 monoclonal antibodies.

The company’s research data was presented during the 2023 European Academy of Allergy and Clinical Immunology (EAACI) Congress, in Hamburg, Germany.

The data shows that nearly all peanut-specific IgE antibodies discovered from peanut-allergic individuals were high affinity, with many exhibiting double-digit picomolar affinity.

Select monoclonal IgG4 antibodies, re-engineered from human IgE antibodies, were able to inhibit allergic plasma IgE from binding recombinant Ara h 2 in vitro, and also inhibit whole peanut-mediated mast cell and basophil activation.

These IgG4 antibodies have the potential to form the basis of a therapeutic drug candidate exhibiting strong potency and efficacy in vitro, ex vivo, and in vivo.

According to IgGenix, this potential new paradigm for food allergy treatment could allow for protection within days of subcutaneous administration without the adverse events and long treatment duration associated with daily allergen administration.

“Peanut allergy is an increasingly prevalent unmet medical need that affects children and adults worldwide. There remains a need for a safe and efficacious therapeutic option with a rapid onset of action that protects against accidental allergen exposure and improves quality of life,” said Derek Croote, PhD, Co-Founder and Chief Technical Officer of IgGenix.

“Through an unbiased human IgE discovery platform, IgGenix has created a powerful foundation from which to generate high-affinity IgG4 antibodies that bind to immunodominant allergens and epitopes on those allergens. These insights provide a potential path to a new standard of care for preventing severe allergic reactions.”

IgGenix uses its SEQ SIFTER discovery platform, developed from foundational research of the co-founders, to isolate and re-engineer fully human, high-affinity, allergen-specific antibodies designed to block and prevent the allergic cascade.

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free